Published in Nature on February 21, 2010
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Rare and common variants: twenty arguments. Nat Rev Genet (2012) 6.67
Human genetic susceptibility to infectious disease. Nat Rev Genet (2012) 2.25
Integrating functional data to prioritize causal variants in statistical fine-mapping studies. PLoS Genet (2014) 1.91
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. Bioinformatics (2014) 1.64
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat (2014) 1.54
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey. PLoS One (2016) 1.41
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis (2011) 1.33
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology (2011) 1.10
Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08
Host genetics and HIV-1: the final phase? PLoS Pathog (2010) 1.06
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat (2012) 1.04
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01
Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol (2010) 0.99
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genet Med (2016) 0.97
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
Management of hepatitis C virus infection: the basics. Top Antivir Med (2012) 0.95
Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium. Am J Hum Genet (2012) 0.94
Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol (2011) 0.94
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2015) 0.93
Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools. Environ Mol Mutagen (2012) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep (2010) 0.92
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis (2011) 0.92
Single-Nucleotide Polymorphisms Within MicroRNAs Sequences and Their 3' UTR Target Sites May Regulate Gene Expression in Gastrointestinal Tract Cancers. Iran Red Crescent Med J (2014) 0.92
Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews. Mol Cell Proteomics (2012) 0.92
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther (2011) 0.91
Predicting signatures of "synthetic associations" and "natural associations" from empirical patterns of human genetic variation. PLoS Comput Biol (2012) 0.90
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses (2012) 0.89
WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC Med Genet (2010) 0.88
Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol (2012) 0.88
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol (2013) 0.87
A tool for mapping Single Nucleotide Polymorphisms using Graphics Processing Units. BMC Bioinformatics (2014) 0.86
Detection of common single nucleotide polymorphisms synthesizing quantitative trait association of rarer causal variants. Genome Res (2011) 0.86
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology (2010) 0.86
Leveraging prior information to detect causal variants via multi-variant regression. PLoS Comput Biol (2013) 0.85
Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J (2013) 0.84
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother (2012) 0.84
Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One (2012) 0.84
Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease. Public Health Genomics (2014) 0.84
What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis (2013) 0.83
Purinergic signalling in the liver in health and disease. Purinergic Signal (2013) 0.83
Host genetic variants in the pathogenesis of hepatitis C. Viruses (2012) 0.82
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PLoS One (2014) 0.82
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother (2015) 0.82
Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet (2013) 0.82
Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in adult hematological malignancy patients and possible association with mitochondrial DNA defects. J Hematol Oncol (2013) 0.82
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol (2013) 0.82
Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol (2012) 0.81
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol (2011) 0.81
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol (2012) 0.81
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol (2015) 0.81
A genome-wide perspective of human diversity and its implications in infectious disease. Cold Spring Harb Perspect Med (2013) 0.80
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol (2014) 0.80
Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant. J Nucleic Acids (2010) 0.80
ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics. Mutat Res (2013) 0.80
Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report. BMC Res Notes (2014) 0.79
Platelet count and sustained virological response in hepatitis C treatment. World J Hepatol (2013) 0.79
Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases (2015) 0.79
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J (2010) 0.79
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J Gastroenterol (2012) 0.79
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. PLoS One (2012) 0.79
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scand J Gastroenterol (2015) 0.79
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One (2015) 0.79
Genomic technology applied to pharmacological traits. JAMA (2011) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Big changes are coming in hepatitis C. Curr Gastroenterol Rep (2011) 0.78
Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study. Pharmacogenet Genomics (2014) 0.78
Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat (2010) 0.78
Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther (2013) 0.78
Individualized medicine 2010. J Cell Mol Med (2010) 0.78
Unraveling the genetic predisposition of ribavirin-induced anaemia. J Hepatol (2010) 0.78
The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core. J Struct Biol (2013) 0.78
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. J Gastroenterol (2015) 0.77
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. J Transl Med (2015) 0.77
ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS One (2015) 0.77
Local Joint Testing Improves Power and Identifies Hidden Heritability in Association Studies. Genetics (2016) 0.77
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype. BMC Gastroenterol (2012) 0.77
Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C. Mem Inst Oswaldo Cruz (2015) 0.77
The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. J Korean Med Sci (2013) 0.77
Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
Pharmacogenomics of antimicrobial agents. Pharmacogenomics (2014) 0.76
Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore. Biomacromolecules (2015) 0.76
A novel approach for identifying causal models of complex diseases from family data. Genetics (2015) 0.76
Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum (2011) 0.76
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One (2013) 0.76
Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver (2015) 0.76
Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther (2012) 0.75
The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Hepat Mon (2016) 0.75
Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenet Genomics (2013) 0.75
Erythrocyte inosine triphosphatase activity is decreased in HIV-seropositive individuals. PLoS One (2012) 0.75
Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis. Int J Med Sci (2013) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
A haplotype map of the human genome. Nature (2005) 105.70
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Common genetic variation and human traits. N Engl J Med (2009) 21.03
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
The global burden of hepatitis C. Liver Int (2009) 8.89
Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol (2005) 7.46
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Drug reactions enzymes, and biochemical genetics. J Am Med Assoc (1957) 2.67
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet (2002) 2.03
Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem (2005) 1.96
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem (2006) 1.60
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab (2005) 1.29
Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes (2009) 1.29
The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta (2006) 1.28
Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics (2007) 1.27
Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol (2009) 1.23
DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet (2002) 1.22
Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit (2007) 1.17
HK Utrecht: missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia. Blood (2002) 1.12
Downeast anemia (dea), a new mouse model of severe nonspherocytic hemolytic anemia caused by hexokinase (HK(1)) deficiency. Blood Cells Mol Dis (2002) 1.02
Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem (1975) 0.97
First mutation in the red blood cell-specific promoter of hexokinase combined with a novel missense mutation causes hexokinase deficiency and mild chronic hemolysis. Haematologica (2009) 0.90
Finding the missing heritability of complex diseases. Nature (2009) 67.95
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Discerning the ancestry of European Americans in genetic association studies. PLoS Genet (2007) 7.81
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol (2002) 5.58
Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet (2013) 5.58
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
Spreading the word. Nature (2007) 5.03
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet (2003) 4.58
Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet (2010) 4.29
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Disparities in liver transplantation before and after introduction of the MELD score. JAMA (2008) 4.10
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol (2004) 3.80
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57